Advertisement

Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence – Estimates from the Finnish prescription register

      Highlights

      • We estimated the cost-effectiveness of statin therapy under real-world adherence.
      • Adherence seems to have a major impact on the cost-effectiveness of statin therapy.
      • Statins do not seem cost-effective for low-risk patients even with full adherence.
      • Ways to improve adherence among patients on statin therapy are needed.

      Abstract

      Objective

      To estimate the cost-effectiveness of statin therapy for primary prevention of coronary heart disease (CHD) events under real-world adherence.

      Methods

      A cost-effectiveness model was applied to estimate the expected 10-year costs and health outcomes (in terms of quality-adjusted life-years, QALYs) associated with and without statin treatment (at defined adherence levels) among hypothetical cohorts of Finnish men and women who were initially without established CHD. Treatment efficacy, cost, and quality of life estimates were obtained from published sources. Long-term treatment adherence was measured based on data from the national prescription register.

      Results

      At an assumed willingness-to-pay threshold of €20,000 per QALY gained, statin treatment with real-world adherence was cost-effective among the older patient groups when the patients’ 10-year CHD risk was as high as 20% and did not seem cost-effective in the youngest age groups. Conversely, statin treatment with full adherence was cost-effective for almost all patient groups with a 10-year CHD risk of at least 15%.

      Conclusions

      Even though generic statins are now low-cost drugs, treatment adherence seems to have a major impact on the cost-effectiveness of statin treatment in primary prevention. This finding stresses the importance of making a concerted effort for improving adherence among patients on statin therapy to obtain full benefit of the investment in statins. Therefore, novel cost-effective approaches to improve treatment adherence are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Taylor F.
        • Huffman M.D.
        • Macedo A.F.
        • et al.
        Statins for the primary prevention of cardiovascular disease.
        Cochrane Database Syst. Rev. 2013; 1: CD004816https://doi.org/10.1002/14651858.CD004816.pub5
        • Neyt M.
        • De Laet C.
        • Van Brabandt H.
        • et al.
        Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
        Acta Cardiol. 2009; 64: 1-10
        • Greving J.P.
        • Visseren F.L.
        • de Wit G.A.
        • Algra A.
        Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
        BMJ. 2011; 342: d1672https://doi.org/10.1136/bmj.d1672
        • Lazar L.D.
        • Pletcher M.J.
        • Coxson P.G.
        • et al.
        Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
        Circulation. 2011; 124: 146-153https://doi.org/10.1161/CIRCULATIONAHA.110.986349
        • Mitchell A.P.
        • Simpson R.J.
        Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.
        BMC Res. Notes. 2012; 5: 373https://doi.org/10.1186/1756-0500-5-373
        • Rikala M.
        • Huupponen R.
        • Helin-Salmivaara A.
        • Korhonen M.J.
        Channelling of statin use towards low-risk population and patients with diabetes.
        Basic Clin. Pharmacol. Toxicol. 2013; 113: 173-178https://doi.org/10.1111/bcpt.12075
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S1-S45https://doi.org/10.1161/01.cir.0000437738.63853.7a
        • Ridker P.M.
        • Cook N.R.
        Statins: new American guidelines for prevention of cardiovascular disease.
        Lancet. 2013; 382: 1762-1765https://doi.org/10.1016/S0140-6736(13)62388-0
        • Rabar S.
        • Harker M.
        • O'Flynn N.
        • et al.
        Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
        BMJ. 2014; 349: g4356https://doi.org/10.1136/bmj.g4356
        • de Vries F.M.
        • Denig P.
        • Visser S.T.
        • et al.
        Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
        Value Health. 2014; 17: 223-230https://doi.org/10.1016/j.jval.2013.12.010
        • Authors/Task Force Members
        • Perk J.
        • De Backer G.
        • et al.
        European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
        Eur. Heart J. 2012; 33: 1635-1701https://doi.org/10.1093/eurheartj/ehs092
        • Lemstra M.
        • Blackburn D.
        • Crawley A.
        • Fung R.
        Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis.
        Can. J. Cardiol. 2012; 28: 574-580https://doi.org/10.1016/j.cjca.2012.05.007
        • Bitton A.
        • Choudhry N.K.
        • Matlin O.S.
        • et al.
        The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review.
        Am. J. Med. 2013; 126 (357.e7–357.e27)https://doi.org/10.1016/j.amjmed.2012.09.004
        • Martikainen J.A.
        • Ottelin A.M.
        • Kiviniemi V.
        • Gylling H.
        Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
        Eur. J. Cardiovasc Prev. Rehabil. 2007; 14: 265-272https://doi.org/10.1097/01.hjr.0000216550.74258.12
        • Peura P.
        • Martikainen J.
        • Soini E.
        • et al.
        Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
        Curr. Med. Res. Opin. 2008; 24: 1823-1832https://doi.org/10.1185/03007990802144705
        • Martikainen J.A.
        • Soini E.J.
        • Laaksonen D.E.
        • Niskanen L.
        Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies.
        Eur. J. Clin. Nutr. 2011; 65: 1148-1155https://doi.org/10.1038/ejcn.2011.78
        • Vartiainen E.
        • Laatikainen T.
        • Salomaa V.
        • et al.
        Sydäninfarkti- ja aivohalvausriskin arviointi FINRISKI-tutkimuksessa (The FINRISK function: estimation of the risk of coronary events and stroke in the Finnish population).
        Fin. Med. J. 2007; 48: 4507-4513
        • Laatikainen T.
        • Pääkkönen R.
        • Keskimäki I.
        • et al.
        Tietokanta sepelvaltimotaudin esiintyvyydestä http://www.ktl.fi/cvdr.
        Fin. Med. J. 2004; 23 (A new internet data base on the occurrence of coronary heart disease in Finland): 2403-2407
        • Häkkinen U.
        • Idänpään-Heikkilä U.
        • Keskimäki I.
        • et al.
        PERFECT – Sydäninfarkti: Sydäninfarktin hoito, kustannukset ja vaikuttavuus.
        Stakes, Helsinki2007 (Available from:) (accessed 22.09.14.)
        • Kiviniemi V.
        • Peura P.
        • Helin-Salmivaara A.
        • et al.
        Suboptimal use of statins at treatment initiation.
        Eur. J. Clin. Pharmacol. 2011; 67: 971-973https://doi.org/10.1007/s00228-011-1037-0
        • Hujanen T.
        • Kapiainen S.
        • Tuominen U.
        • Pekurinen M.
        Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006.
        Stakes, Helsinki2010 (Available from:) (accessed 22.09.14.)
      1. Acute Coronary Syndrome: Unstable Angina and Myocardial Infarction without ST Elevation (online). Current Care Guidelines. Working Group Set up by the Finnish Medical Society Duodecim and the Finnish Cardiac Society. The Finnish Medical Society Duodecim, Helsinki2014 (Available from:) (accessed 22.09.14.)
        • Vehviläinen A.
        • Hartikainen J.
        • Niskanen L.
        • Vohlonen I.
        Työikäisten sepelvaltimotautipotilaiden hoidon kokonaiskustannukset (The costs of inpatient treatment of ischaemic heart disease patients).
        Fin. Med. J. 2004; 3: 181-186
        • Saarni S.I.
        • Harkanen T.
        • Sintonen H.
        • et al.
        The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D.
        Qual. Life Res. 2006; 15: 1403-1414https://doi.org/10.1007/s11136-006-0020-1
        • Soini E.J.
        • Davies G.
        • Martikainen J.A.
        • et al.
        Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland.
        Curr. Med. Res. Opin. 2010; 26: 25-36https://doi.org/10.1185/03007990903422620
        • Aarnio E.J.
        • Martikainen J.A.
        • Helin-Salmivaara A.
        • et al.
        Register-based predictors of adherence among new statin users in Finland.
        J. Clin. Lipidol. 2014; 8: 117-125https://doi.org/10.1016/j.jacl.2013.09.008
        • Peterson A.M.
        • Nau D.P.
        • Cramer J.A.
        • et al.
        A checklist for medication compliance and persistence studies using retrospective databases.
        Value Health. 2007; 10: 3-12https://doi.org/10.1111/j.1524-4733.2006.00139.x
        • Romppainen T.
        • Rikala M.
        • Aarnio E.
        • et al.
        Measurement of statin exposure in the absence of information on prescribed doses.
        Eur. J. Clin. Pharmacol. 2014; 70: 1275-1276https://doi.org/10.1007/s00228-014-1737-3
        • Rasmussen J.N.
        • Chong A.
        • Alter D.A.
        Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.
        JAMA. 2007; 297: 177-186https://doi.org/10.1001/jama.297.2.177
        • Ruokoniemi P.
        • Korhonen M.J.
        • Helin-Salmivaara A.
        • et al.
        Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study.
        Br. J. Clin. Pharmacol. 2011; 71: 766-776https://doi.org/10.1111/j.1365-2125.2010.03895.x
        • Helin-Salmivaara A.
        • Korhonen M.J.
        • Lehenkari P.
        • et al.
        Statins and hip fracture prevention–a population based cohort study in women.
        PLoS One. 2012; 7: e48095https://doi.org/10.1371/journal.pone.0048095
        • Law M.R.
        • Wald N.J.
        • Thompson S.G.
        By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?.
        BMJ. 1994; 308: 367-372
        • Cherry S.B.
        • Benner J.S.
        • Hussein M.A.
        • et al.
        The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients.
        Value Health. 2009; 12: 489-497https://doi.org/10.1111/j.1524-4733.2008.00447.x
        • Briggs A.H.
        • Goeree R.
        • Blackhouse G.
        • O'Brien B.J.
        Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease.
        Med. Decis. Mak. 2002; 22: 290-308
        • van Kempen B.J.
        • Ferket B.S.
        • Hofman A.
        • et al.
        Do different methods of modeling statin treatment effectiveness influence the optimal decision?.
        Med. Decis. Mak. 2012; 32: 507-516https://doi.org/10.1177/0272989X12439754
        • Maningat P.
        • Gordon B.R.
        • Breslow J.L.
        How do we improve patient compliance and adherence to long-term statin therapy?.
        Curr. Atheroscler. Rep. 2013; 15: 291https://doi.org/10.1007/s11883-012-0291-7
        • Kavousi M.
        • Leening M.J.
        • Nanchen D.
        • et al.
        Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
        JAMA. 2014; 311: 1416-1423https://doi.org/10.1001/jama.2014.2632
        • Goff Jr., D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • et al.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S49-S73https://doi.org/10.1161/01.cir.0000437741.48606.98
        • Hippisley-Cox J.
        • Coupland C.
        • Vinogradova Y.
        • et al.
        Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.
        BMJ. 2008; 336: 1475-1482https://doi.org/10.1136/bmj.39609.449676.25
        • Teramoto T.
        • Sasaki J.
        • Ishibashi S.
        • et al.
        Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version.
        J. Atheroscler. Thromb. 2013; 20: 517-523https://doi.org/10.5551/jat.15792
        • Mann D.M.
        • Allegrante J.P.
        • Natarajan S.
        • et al.
        Predictors of adherence to statins for primary prevention.
        Cardiovasc Drugs Ther. 2007; 21: 311-316https://doi.org/10.1007/s10557-007-6040-4
        • Finegold J.A.
        • Manisty C.H.
        • Goldacre B.
        • et al.
        What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice.
        Eur. J. Prev. Cardiol. 2014; 21: 464-474https://doi.org/10.1177/2047487314525531
        • Harper C.R.
        • Jacobson T.A.
        Evidence-based management of statin myopathy.
        Curr. Atheroscler. Rep. 2010; 12: 322-330https://doi.org/10.1007/s11883-010-0120-9
        • Emerging Risk Factors Collaboration
        • Sarwar N.
        • Gao P.
        • et al.
        Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
        Lancet. 2010; 375: 2215-2222https://doi.org/10.1016/S0140-6736(10)60484-9